[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. Enjoy!] Readers not familiar with Stock Gumshoe usually arrive wondering if the salivation provoked by stock promotional writers for certain companies is justified. […]
Articles
- Most Relevant
- Most Recent
Entry level newsletter with the stated aim of “uncovering the stocks that pay you first,” with a focus on dividends, buybacks and paying down debt. This publication has been closed.
[Ed note: This article was originally published in June, 2013 when the shares of the stock teased, Alnylam (ALNY) were around $30 and the Oxford Club was saying that the first person to live to 1,000 is already alive … now they’re touting it as the holder of the “Magic” Keys to Immortality, but the […]
[Ed. Note: Dr. KSS writes about medicine and biotech for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. Enjoy!] Conclusion of a Series on Pain [This column is dedicated to recovery from a recent cancer diagnosis of a stuff-of-legend friend whose life I cherish. She recently […]
Originally published on May 30, 2017 Keith Fitz-Gerald is out with a new ad for his Money Map Report that promises you can “claim” payments from big tobacco — and, naturally, Gumshoe readers are curious… is there really some way that normal folks like you and I can “collect thousands of dollars a month, tax-free, […]
Today we’ve got a teaser pitch from Marc Lichtenfeld to consider. It’s an ad for his Oxford Income Letter, but the “fountain of youth” pitch makes it sound like a wild ride of a biotech idea… so let’s dig in and see what we can find, shall we? Sometimes it’s best to start with the […]
Stansberry & Associates’ Phase 1 Investor newsletter is teasing us about shares of a drug company: “On March 30, FDA results we’ve waited 2 years to receive could make you $195,600, overnight” — and they quote Porter Stansberry as saying that “This is the kind of situation that can change your life… where a $10,000 stake can allow you to literally quit work, forever.” Sounds nice, eh?
Antibiotic resistance is a big deal, as you undoubtedly already know — and resistant strains of various cooties are becoming more and more of a problem, particularly in hospital settings where they seem to spread like wildfire among the sick, infirm and open-wounded, but elsewhere as well. And the new wave of antibiotics is certainly […]
And we’re back! Today, it’s a biotech teaser from Brian Hicks for Steve Christ’s The Wealth Advisory (we last looked at one of his a few months back, when he was predicting a big move in Geron by this Spring — that one’s still on the clock, so we’ll see). This time the tease is […]
Another biotech teaser for you today — these never seem to stop, perhaps partly because small biotech stocks are almost the only ones, other than little junior miners, that have a legitimate chance of seeing their prospects change dramatically overnight or see rapid 100%, 200%, 500% share price gains on a new discovery or shockingly […]
Steve McDonald made some friends in the world of Gumshoe a few years ago, when his income-focused advisory The Bond Trader was doing pretty well. He moved on from that to a service with a similar strategy for the Oxford Club folks called Oxford Bond Advantage, and he’s now pitching that newsletter by tantalizing readers […]
This ad has been rolling around here at Stock Gumshoe, but I haven’t had a chance to look at it until today… and a few new readers asked about it just recently, so I’m taking my chance now… with the caveat that I last saw the ad circulated about a month ago, so I can’t […]
I’ve been getting a lot of questions about the latest “teaser video” from Patrick Cox for his Breakthrough Technology Alert — it’s the one that starts with a story about how “Robert has Alzheimer’s” and that a “breakthrough” gives him hope. And, of course, Cox will be “forced to remove” the presentation on November 11, […]
Nick Hodge has been touting “next big thing” materials stocks for as long as Stock Gumshoe has been around, from rare earth magnets to graphite and uranium and lithium and cobalt and pretty much any other heavily-hyped stuff you might imagine digging out of the ground… and his latest pitch is about what is arguably […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. His previous columns can be found here. Enjoy!] Every New Year, a friend and I flew to Boston. She’d gone to medical school […]
This percolated up to the “most asked about” teaser pitch over the weekend, and it’s easy to see why — everyone loves royalties (or as the newsletters like to call it, “getting money for free without doing any hard work”), and Sid Riggs is saying that “you can get super rich in a matter of […]
This is actually an odd little teaser that a few readers sent in to me recently — including one who offered a solution that is actually correct (forgot to ask for permission, so I won’t mention the name). Smart readers here, as always. What we get here, in exchange for subscribing to Steve Sjuggerud’s True […]
That’s a subtle headline, right? I already issued a bit of a “brain dump” for the Irregulars this week, on Wednesday instead of Friday, but I couldn’t resist taking a little look at this latest teaser pitch from Patrick Cox for his Transformational Technology Alert. Quite a few readers have been asking about it, and […]
I always love to see a new teaser from Phase 1 Investor, the high-price newsletter offered as the “ultimate upgrade” by the Stansberry & Associates folks — the stocks usually are interesting, they’re often tiny and move like crazy after the teaser campaign, and the marketing language is always plenty florid to justify the $5,000 […]
I always love to see a new teaser from Phase 1 Investor, the high-price newsletter offered as the “ultimate upgrade” by the Stansberry & Associates folks — the stocks usually are interesting, they’re often tiny and move like crazy after the teaser campaign, and the marketing language is always plenty florid to justify the $5,000 […]
Jim Woods “Grow Richer on the Crypto Boom Without Risking a Cent on Dangerous Digital Currencies”Does anyone know the “5 Crypto Blockbusters” that Jim Woods mentions in his Intelligence Report newsletter? He claims you can “Grow Richer on the Crypto Boom Without Risking 1 Red Cent on Dangerous Digital Currencies“.
This is the first discussion I’ve ever started and around sure if this is how to draw some interest from Travis to explore this teaser, but anyway. Here is Junior Mining Trader. One of the OutsiderClub.com newsletters They want $2000 for a one-year subscription on this teaser. Here’s the web address https://secure.outsiderclub.com/o/web/313984 The #1 Gold […]
Monthly stock and option trading advisory, offers up 4-6 trades/month and weekly updates.
Jim had a “seminar” on-line today touting his $20 backdoor bitcoin trade, a bitcoin brokerage company that is the full-service digital broker that is going to be more profitable than any other bitcoin play. Only thing is, you have to subscribe to his relatively expensive newsletter to learn who it is. Hmmm, what does the […]
The Motley Fool in recent weeks has been ramping up their teaser pitches on the weekend over the past few weeks, sending quite a few questions our way — most of these have been pitches for their higher-end portfolio services like the various Extreme Opportunities services, and that’s also what has caught our eye this […]
Nick Hodge and Gerardo del Real did not disappear for long when their newsletters stopped being published by the Outside Club… they’re back with new letters from a publisher they’re now calling Daily Profit, including Gerardo del Real’s Junior Resource Monthly (currently “on sale” for $99, this is effectively a restart of the Junior Mining […]
This email hit the inbox and caught my eye today, from publisher Roger Michalski for one of the Eagle Financial publications: “Seeing that consumers — the driving force behind our economy — are consuming in record numbers online… “e-Commerce certainly is the place to be. “The profit numbers shown here prove it. “But where is […]
1/5/21 Jim Woods is teasing a crypto middleman stock that can be traded in the US and Canada. He is tempting folks to subscribe to his Bullseye Stock Trader service, a part of Eagle Publications. Have any ideas of the stock to which he is referring? Thanks. galefb Atlanta, GA
Anyone have a line on this teaser? Play to make prior to election on Tuesday? Thanks!
Similar to the Junior Mining Monthly that Del Real wrote for Outsider Club, published until October of 2020. Natural resources investment advisory, with monthly issues recommending junior mining stocks.
Received emails on Friday (10/17) that Del Real (Junior Mining Monthly / Trader) and Nick Hodge (Wallstreet Underground Profits) both from the The Outsider Club newsletter had abruptly left The Outside Club for “greener pastures”. Another email referring to Del Real state his departure was under “a disappointing string of events”. The Outsider Club (Angel […]
To be double the size of CBD but is illegal in most states but has momentum with the multiple natural cures from the mushrooms. Going before congress seeking to gain favorable status, June 19th.
Can you speak to the predications of Jim Rickards and the collapse of America? Also, what are the 5 steps to take now to avoid losing everything?
I found this off of Market Watch. I’m Rickards may be one of the most well-known government “insiders” in the world… Which is remarkable considering he’s never held public office before. But whenever Jim releases a new prediction, people take notice. That’s because his track record of predictions seems to be flawless. Today, Jim filmed […]
The latest ads from Cabot’s Global Stocks Explorer caught my eye with a “bypass the coronavirus” pitch. Here’s how the ad starts: “Bypass the Coronavirus…with this hidden gem at the heart of ‘the biggest investment boom in history’ “Operating revenue increased over 70%. “Gross profit surged 122%. “Net income was up over 60%. “Total bookings […]
This article was originally published back in August, 2019 when we were getting lots of questions about Chris Wood’s teaser pitch — the ad is still largely the same, most of the hints and projections are identical and he still expects that February 2020 approval will send the stock soaring (yes, we’re still getting this […]
Have you ever heard the quote, “nothing tastes as good as thin feels?” Such sayings have been attributed to waif model Kate Moss, plenty of her anorexic fans, and dozens of others in the perfection industry (including Stephen Covey), and I’ll confess that the sentiment has never resonated with me even a little bit (as […]
I’m still able to generate some enthusiasm about specific stocks that I think are appealing enough to buy at these prices… but I find it very hard to be optimistic in a macro sense right now, it really feels to me as though the market is whistling past the graveyard and being far too sanguine […]
We’re used to seeing biotech stocks surge because of the results of a clinical trial… but it’s quite crazy to see the whole market pinning its hopes on a clinical trial. Gilead’s (GILD) Remdisivir had some weak results leak last week and that helped inspire the market selloff (“Oh no, we won’t get a drug […]
FOR EXPONENTIAL TECH, regarding a small biotech: ”In July 2018, this biotech announced positive results for its Phase 1 clinical trials. And get this. This drug has been used for many years in Japan with few adverse side effects. Because of this, the FDA granted the drug a qualified infectious disease product designation. In other […]